Lung cancer patients get a second shot: CyberKnife boost after chemoradiation

NCT ID NCT06627738

Recruiting now Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether adding a precise, high-dose radiation boost (CyberKnife) after standard chemoradiation can help keep locally advanced non-small cell lung cancer from progressing. About 42 patients who cannot have surgery will receive the boost. The main goal is to see how many are still cancer-free or alive after two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CyberKnife radiation boost
What this could lead to: If successful, this approach could improve the chance of keeping lung cancer from growing back for at least two years after standard chemoradiation.
What could go wrong: This is a small, early-phase trial with only 42 participants and no comparison group, so results may not apply broadly. The extra radiation also carries risks like lung inflammation or damage to nearby organs.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Centre Antoine Lacassagne
RECRUITING

Nice, 06000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.